Patent Application

App. No. 18/632,996

Abstract

Claims (31)

1 .- 61 . (canceled)

62 . A method of preventing myocardial infarction in a human in need thereof comprising administering to the human a therapeutically effective amount of a pharmaceutical material comprising the compound of formula (V):

wherein the pharmaceutical material comprises the compound of formula (V) in an amount greater than 98% by weight based on the total weight of the pharmaceutical material, and the pharmaceutical material comprises a compound of formula (VI):

or a pharmaceutically acceptable salt thereof, wherein the compound of formula (VI), or a pharmaceutically acceptable salt thereof, is present in an amount between 0.001% to 0.15% based on the total weight of the pharmaceutical material.

63 . The method of claim 62 , wherein the compound of formula (V) is a crystalline form of the compound of formula (V).

64 . The method of claim 63 , wherein the crystalline form of the compound of formula (V) exhibits an X-ray powder diffraction pattern comprising peaks at the following diffraction angles (2θ): 10.4±0.2, 17.9±0.2, 18.8±0.2, 19.5±0.2, and 20.7±0.2.

65 . The method of claim 63 , wherein the compound of formula (V) is characterized by an X-ray powder diffraction pattern the same as shown in FIG. 4 .

66 . The method of claim 63 , wherein the crystalline form of the compound of formula (V) has a melting point onset as determined by differential scanning calorimetry in a range from 90° C. to 94° C.

67 . The method of claim 63 , wherein the pharmaceutical material comprises the compound of formula (V), or a pharmaceutically acceptable salt thereof, in an amount greater than 99% by weight based on the total weight of the pharmaceutical material.

68 . The method of claim 63 , wherein the pharmaceutical material comprises the compound of formula (V), or a pharmaceutically acceptable salt thereof, in an amount greater than 99.5% by weight based on the total weight of the pharmaceutical material.

69 . The method of claim 62 , further comprising administering a second therapeutic agent, wherein the second therapeutic agent is ezetimibe.

70 . A method of preventing myocardial infarction in a human in need thereof comprising administering to the human a therapeutically effective amount of a pharmaceutical material comprising the compound of formula (V):

wherein the pharmaceutical material comprises the compound of formula (V) in an amount of from 98% to 102% by weight based on the total weight of the pharmaceutical material, as determined by a high performance liquid chromatography (HPLC) assay; and the pharmaceutical material comprises a compound of formula (VI):

or a pharmaceutically acceptable salt thereof, wherein the compound of formula (VI), or a pharmaceutically acceptable salt thereof, is present in an amount between 0.001% to 0.15% based on the total weight of the pharmaceutical material.

71 . The method of claim 70 , wherein the HPLC assay uses a C18 column having the dimensions 4.6 mm i.d.×150 mm, with a particle size of 2.5 μm, at a temperature of 40° C., with isocratic elution of a mobile phase comprising 0.05% phosphoric acid in 50:50 water/acetonitrile at a flow rate of 1.2 mL/minute, and detection at 215 nm, wherein the retention time of the compound of formula (V) is 4.6 minutes.

72 . The method of claim 70 , wherein the pharmaceutical material has a melting point onset as determined by differential scanning calorimetry in a range from 90° C. to 94° C.

73 . The method of claim 70 , wherein the pharmaceutical material comprises the compound of formula (V) in an amount greater than 99% by weight based on the total weight of the pharmaceutical material.

74 . The method of claim 70 , further comprising administering a second therapeutic agent, wherein the second therapeutic agent is ezetimibe.

75 . A method of preventing myocardial infarction in a human in need thereof comprising administering to the human a therapeutically effective amount of a pharmaceutical formulation comprising:

a pharmaceutical material comprising the compound of formula (V):

wherein the compound of formula (V) is present in an amount greater than 85% by weight based on the total weight of the pharmaceutical material, and

a compound of formula (VI):

or a pharmaceutically acceptable salt thereof, wherein the compound of formula (VI), or a pharmaceutically acceptable salt thereof, is present in an amount between 0.001% to 0.15% based on the total weight of the pharmaceutical material; and

a pharmaceutically acceptable excipient,

wherein the pharmaceutical formulation is prepared using a crystalline form of the compound of formula (V).

76 . The method of claim 75 , wherein the crystalline form of the compound of formula (V) exhibits an X-ray powder diffraction pattern comprising peaks at the following diffraction angles (2θ): 10.4±0.2, 17.9±0.2, 18.8±0.2, 19.5±0.2, and 20.7±0.2.

77 . The method of claim 75 , wherein the crystalline form of the compound of formula (V) has a melting point onset as determined by differential scanning calorimetry in a range from 90° C. to 94° C.

78 . The method of claim 75 , wherein the pharmaceutical material comprises the compound of formula (V) in an amount greater than 90% by weight based on the total weight of the pharmaceutical material.

79 . The method of claim 75 , wherein the pharmaceutical material comprises the compound of formula (V) in an amount greater than 95% by weight based on the total weight of the pharmaceutical material.

80 . The method of claim 75 , wherein the pharmaceutical material comprises the compound of formula (V) in an amount greater than 97% by weight based on the total weight of the pharmaceutical material.

81 . The method of claim 75 , further comprising administering a second therapeutic agent, wherein the second therapeutic agent is ezetimibe.

Assignments (11)